Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus gemcitabine versus placebo plus gemcitabine in first-line metastatic pancreatic adenocarcinoma
2010-020398-18Phase 3Terminated
- Sponsor
- Amgen
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing AMG 479 plus gemcitabine with Placebo plus gemcitabine (2 arms). Primary endpoint: Overall survival. Started Nov 2010; status: terminated.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-020398-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020398-18.